This test-negative case-control study found RSV vaccine effectively reduces hospitalization in older adults, suggesting high importance for vaccination.
Key Points
The RSV vaccine reduced hospitalization by 58% during two seasons for adults aged 60 and older, indicating effectiveness.
Among immunocompetent adults, vaccine effectiveness was 67%, but only 30% for the immunocompromised, highlighting disparity.
Analysis involved 6958 adults hospitalized for acute respiratory illness across 26 hospitals in 20 US states, focusing on RSV cases.
Lower vaccine effectiveness was observed in those with cardiovascular disease, indicating a need for tailored vaccine strategies.